SunTrust Robinson Humphrey Starts Clovis Oncology (CLVS) at Buy
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
SunTrust Robinson Humphrey initiated coverage on Clovis Oncology (NASDAQ: CLVS) with a Buy rating and a price target of $25.00.
Shares of Clovis Oncology closed at $15.44 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Chardan Capital Markets Starts Clovis Oncology (CLVS) at 'Sell' With Price Target of $15
- Needham & Company Starts AMAG Pharmaceuticals (AMAG) at Buy
- Sprint (S) PT Raised to $4.50 at Jefferies
Create E-mail Alert Related CategoriesHot New Coverage, New Coverage
Related EntitiesSunTrust Robinson Humphrey
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!